| Bioactivity | C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5]. |
| Invitro | C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR−/− but not PAFR+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR−/− cells infected with EGFP alone[1]. C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR−/− neurons[1]. C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor[2][3]. C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner[3]. Cell Viability Assay[1] Cell Line: |
| Name | C16-PAF |
| CAS | 74389-68-7 |
| Formula | C26H54NO7P |
| Molar Mass | 523.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |